IAE0972 + capecitabine

Capecitabine is an orally administered small molecule chemotherapeutic agent classified as an antimetabolite. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in tumor tissues, where it inhibits DNA synthesis and slows the growth of cancer cells. Capecitabine is used alone or in combination with other agents to treat various cancers including breast cancer, colon cancer, rectal cancer, esophageal and gastric cancers, and pancreatic cancer. Its primary mechanism involves interfering with DNA synthesis by acting as a nucleoside metabolic inhibitor[1][3][4][7]. The main brand name for capecitabine is Xeloda[2][3]. IAE0972 does not appear in major drug databases or literature; no information on its structure, mechanism of action, developer or clinical status could be found from the provided sources.

Other names

Ecansyafluoropyrimidine carbamate5-fluorouracil prodrug